Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 5;11(1):273.
doi: 10.3390/jcm11010273.

CPAP Intervention as an Add-On Treatment to Lipid-Lowering Medication in Coronary Artery Disease Patients with Obstructive Sleep Apnea in the RICCADSA Trial

Yeliz Celik  1 , Baran Balcan  2 , Yüksel Peker  1   2   3   4   5
Affiliations

CPAP Intervention as an Add-On Treatment to Lipid-Lowering Medication in Coronary Artery Disease Patients with Obstructive Sleep Apnea in the RICCADSA Trial

Yeliz Celik et al. J Clin Med. .

Abstract

Dyslipidaemia is a well-known risk factor for coronary artery disease (CAD), and reducing lipid levels is essential for secondary prevention in management of these high-risk individuals. Dyslipidaemia is common also in patients with obstructive sleep apnea (OSA). Continuous positive airway pressure (CPAP) is the first line treatment of OSA. However, evidence of a possible lipid-lowering effect of CPAP in CAD patients with OSA is scarce. We addressed the effect of CPAP as an add-on treatment to lipid-lowering medication in a CAD cohort with concomitant OSA. This study was a secondary analysis of the RICCADSA trial (Trial Registry: ClinicalTrials.gov; No: NCT00519597), that was conducted in Sweden between 2005 and 2013. In total, 244 revascularized CAD patients with nonsleepy OSA (apnea-hypopnea index ≥ 15/h, Epworth Sleepiness Scale score < 10) were randomly assigned to CPAP or no-CPAP. Circulating triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) levels (all in mg/dL) were measured at baseline and 12 months after randomization. The desired TG levels were defined as circulating TG < 150 mg/dL, and LDL levels were targeted as <70 mg/dL according to the recent guidelines of the European Cardiology Society and the European Atherosclerosis Society. A total of 196 patients with available blood samples at baseline and 12-month follow-up were included (94 randomized to CPAP, 102 to no-CPAP). We found no significant between-group differences in circulating levels of TG, TC, HDL and LDL at baseline and after 12 months as well as in the amount of change from baseline. However, there was a significant decline regarding the proportion of patients with the desired TG levels from 87.2% to 77.2% in the CPAP group (p = 0.022), whereas there was an increase from 84.3% to 88.2% in the no-CPAP group (n.s.). The desired LDL levels remained low after 12 months in both groups (15.1% vs. 17.2% in CPAP group, and 20.8% vs. 18.8% in no-CPAP group; n.s.). In a multiple linear regression model, the increase in the TG levels was predicted by the increase in body-mass-index (β = 4.1; 95% confidence interval (1.0-7.1); p = 0.009) adjusted for age, sex and CPAP usage (hours/night). CPAP had no lipid-lowering effect in this revascularized cohort with OSA. An increase in body-mass-index predicted the increase in TG levels after 12 months, suggesting that lifestyle modifications should be given priority in adults with CAD and OSA, regardless of CPAP treatment.

Keywords: CPAP; coronary artery disease; dyslipidaemia; obstructive sleep apnea; randomized controlled trial.

PubMed Disclaimer

Conflict of interest statement

Yüksel Peker received institutional grants from ResMed for the main RICCADSA trial. Yeliz Celik and Baran Balcan report no conflict of interest.

Figures

Figure 1
Figure 1
Consort flow chart of the study population.
Figure 2
Figure 2
Distribution of the circulating lipid levels at baseline and after 12 months in patients in the CPAP and no-CPAP groups.
Figure 3
Figure 3
Proportion of participants with the desired triglyceride and low-density lipoprotein levels at baseline and after 12 months.
Figure 4
Figure 4
Multiple linear regression line for the association between change in body-mass-index and change in circulating triglyceride levels after 12 months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2019;41:111–188. doi: 10.1093/eurheartj/ehz455. - DOI - PubMed
    1. Navar-Boggan A.M., Peterson E.D., D’Agostino S.R.B., Neely B., Sniderman A.D., Pencina M.J. Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. Circulation. 2015;131:451–458. doi: 10.1161/CIRCULATIONAHA.114.012477. - DOI - PMC - PubMed
    1. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S. The Occurrence of Sleep-Disordered Breathing among Middle-Aged Adults. N. Engl. J. Med. 1993;328:1230–1235. doi: 10.1056/NEJM199304293281704. - DOI - PubMed
    1. Peppard P.E., Young T., Barnet J.H., Palta M., Hagen E.W., Hla K.M. Increased Prevalence of Sleep-Disordered Breathing in Adults. Am. J. Epidemiol. 2013;177:1006–1014. doi: 10.1093/aje/kws342. - DOI - PMC - PubMed
    1. Gunduz C., Basoglu O.K., Kvamme J.A., Verbraecken J., Anttalainen U., Marrone O., Steiropoulos P., Roisman G., Joppa P., Hein H., et al. Long-term positive airway pressure therapy is associated with reduced total cholesterol levels in patients with obstructive sleep apnea: Data from the European Sleep Apnea Database (ESADA) Sleep Med. 2020;75:201–209. doi: 10.1016/j.sleep.2020.02.023. - DOI - PubMed

Associated data